Literature DB >> 30917957

Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.

Claire Kizlik-Masson1, Quentin Deveuve1, Yuhang Zhou2, Caroline Vayne1,2,3, Gilles Thibault1,2,3,4, Steven E McKenzie2, Claire Pouplard1,2,3, Stéphane Loyau5, Yves Gruel1,2,3, Jérôme Rollin1,2,3.   

Abstract

Heparin-induced thrombocytopenia (HIT) is due to immunoglobulin G (IgG) antibodies, which bind platelet factor 4 (PF4) modified by polyanions, such as heparin (H). IgG/PF4/polyanion complexes directly activate platelets via Fc gamma type 2 receptor A (FcγRIIA) receptors. A bacterial protease, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), cleaves the hinge region of heavy-chain IgG, abolishing its ability to bind FcγR, including FcγRIIA. We evaluated whether cleavage of anti-PF4/H IgG by IdeS could suppress the pathogenicity of HIT antibodies. IdeS quickly cleaved purified 5B9, a monoclonal chimeric anti-PF4/H IgG1, which led to the formation of single cleaved 5B9 (sc5B9), without any reduction in binding ability to the PF4/H complex. However, as compared with uncleaved 5B9, the affinity of sc5B9 for platelet FcγRIIA was greatly reduced, and sc5B9 was also unable to induce heparin-dependent platelet activation. In addition, incubating IdeS in whole blood containing 5B9 or HIT plasma samples led to cleavage of anti-PF4/H antibodies, which fully abolished the ability to induce heparin-dependent platelet aggregation and tissue factor messenger RNA synthesis by monocytes. Also, when whole blood was perfused in von Willebrand factor-coated microfluidic channels, platelet aggregation and fibrin formation induced by 5B9 with heparin was strongly reduced after IdeS treatment. Finally, IdeS prevented thrombocytopenia and hypercoagulability induced by 5B9 with heparin in transgenic mice expressing human PF4 and FcγRIIA receptors. In conclusion, cleavage of anti-PF4/H IgG by IdeS abolishes heparin-dependent cellular activation induced by HIT antibodies. IdeS injection could be a potential treatment of patients with severe HIT.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30917957     DOI: 10.1182/blood.2019000437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

2.  Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.

Authors:  Kandace Gollomp; Amrita Sarkar; Sanjiv Harikumar; Steven H Seeholzer; Gowthami M Arepally; Kristin Hudock; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2020-03-05       Impact factor: 25.476

Review 3.  Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management.

Authors:  Matteo Marchetti; Maxime G Zermatten; Debora Bertaggia Calderara; Alessandro Aliotta; Lorenzo Alberio
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241

4.  PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia.

Authors:  Caroline Vayne; Jérôme Rollin; Yves Gruel; Claire Pouplard; Hubert Galinat; Olivier Huet; Vincent Mémier; Thomas Geeraerts; Raphael Marlu; Gilles Pernod; Guillaume Mourey; Alexandra Fournel; Charlotte Cordonnier; Sophie Susen
Journal:  N Engl J Med       Date:  2021-05-19       Impact factor: 91.245

5.  Discovery of exolytic heparinases and their catalytic mechanism and potential application.

Authors:  Qingdong Zhang; Hai-Yan Cao; Lin Wei; Danrong Lu; Min Du; Min Yuan; Deling Shi; Xiangxue Chen; Peng Wang; Xiu-Lan Chen; Lianli Chi; Yu-Zhong Zhang; Fuchuan Li
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

6.  Reply to the letter entitled "Suggested treatment of serious complications to Covid-19 vaccination with IdeS, a bacterial antibody-cleaving enzyme".

Authors:  Yves Gruel; Caroline Vayne; Jérôme Rollin; Claire Pouplard
Journal:  J Thromb Haemost       Date:  2021-07-30       Impact factor: 16.036

7.  Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al.

Authors:  Fredrik Kahn; Oongh Shannon; Lars Björck
Journal:  J Thromb Haemost       Date:  2021-08-05       Impact factor: 16.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.